What Are Peptide Bioregulators? (Khavinson Peptides) Research Overview

Peptide bioregulators are short peptides — often di-, tri-, or tetrapeptides, or tissue-derived peptide complexes — that have been studied for tissue-specific regulatory effects. They were developed largely by Vladimir Khavinson and colleagues in Russia and have been investigated primarily in gerontology and cell-regulation research. This article is an educational overview for researchers comparing compounds discussed in the peptide literature.

Research-use-only (RUO) note: the compounds described here are discussed strictly in the context of laboratory and preclinical research. Nothing below is medical advice, and no human use is described or implied. Bolt Peptide does not sell the bioregulator family described here.

What are peptide bioregulators?

“Peptide bioregulator” is the term used in the Russian research lineage led by Khavinson to describe short peptides proposed to act as tissue-specific regulators. The central hypothesis of this body of work is that organ function is regulated in part by short peptides produced locally within each tissue, and that an age-related decline in these peptides may contribute to tissue dysfunction in the animal models studied. Two product families emerged from this concept: tissue-extracted complexes the researchers branded “cytomaxes,” and synthetic short peptides branded “cytogens.” Across this literature, the proposed mechanism centers on peptide-level regulation of gene expression and protein synthesis within target tissues — a hypothesis that remains under study rather than an established fact.

The two main types

• Natural peptide complexes (“cytomaxes”) — the first-generation preparations: peptide fractions extracted from specific animal tissues (for example, thymus or pineal gland). These are multi-component fractions rather than single defined peptides.
• Short synthetic peptides (“cytogens”) — the second-generation compounds: chemically synthesized di-, tri-, and tetrapeptides with defined amino-acid sequences, designed after researchers proposed which short sequences were the active components of the cytomax fractions.

Common bioregulators studied in the literature

The following compounds appear in the peptide-bioregulator research literature, grouped by the tissue each is associated with. They are listed here only as research-studied compounds:

• Pineal — Epithalon (synthetic) / Epithalamin (complex)
• Thymus — Thymalin (complex) / Thymogen (synthetic)
• Vascular — Vesugen
• Brain / CNS — Pinealon, Cortexin
• Liver — Livagen
• Pancreas — Pancragen
• Bone / cartilage — Sigumir
• Prostate — Prostamax
• Bronchial — Bronchogen
• Heart — Cardiogen
• Immune — Vilon

What does the research show?

Most of the published work on peptide bioregulators reports preclinical (animal and cell-culture) findings, alongside some clinical research, and originates largely from a single research lineage. A review by Khavinson and colleagues summarized long-term experimental studies describing effects of peptide bioregulators on lifespan and carcinogenesis in laboratory animals, framing them as a proposed class of geroprotectors (Khavinson et al., 2012). Because this literature is concentrated within one institutional tradition, independent replication remains limited, and the findings should be read as a research hypothesis under continued investigation rather than as established conclusions.

Mechanisms studied in the lab

• Tissue-specific regulation — the proposal that each peptide preferentially influences the tissue it was derived from.
• Peptide–DNA / gene-expression hypothesis — a model in which short peptides interact with regulatory regions of DNA to modulate gene expression; this remains a hypothesis under study.
• Telomere / senescence work — for the pineal tetrapeptide Epithalon (Ala–Glu–Asp–Gly), one cell-culture study reported induction of telomerase activity and telomere elongation in human somatic (fetal fibroblast) cells (Khavinson et al., 2003).

Research status

Several of these preparations have been registered for use in Russia, where much of the original research was conducted — that is a matter of historical record. However, none of the peptide bioregulators discussed here are approved by the U.S. Food and Drug Administration (FDA) for any use. In the United States, materials of this kind are handled strictly as research-use-only (RUO) chemicals and are not drugs, supplements, or treatments.

Related research peptides

Researchers exploring this area often compare bioregulators with better-characterized peptides. Browse the full research peptide catalog, or read the related overviews on Epithalon, Thymalin, and Thymosin Alpha-1.

FAQ

Are peptide bioregulators the same as “Khavinson peptides”? “Khavinson peptides” is an informal name for this family, after Vladimir Khavinson, whose group developed and studied most of these compounds. The two terms are used interchangeably in the literature.

What is the difference between Epithalon and Epithalamin? Epithalamin is the natural pineal peptide complex (“cytomax”), while Epithalon is the synthetic tetrapeptide (“cytogen”) proposed as one of its active sequences. Both are associated with the pineal gland in the research.

Are these approved or proven for human use? No. None are FDA-approved, and the available data are largely preclinical and concentrated within one research tradition. They are discussed here only as research compounds, with no human use described or implied.

References

1. Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: the new class of geroprotectors. Adv Gerontol. 2012.
2. Khavinson VKh, et al. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003.

For research use only. None of these compounds are FDA-approved; Russian registration is historical fact only and does not imply US approval. Not for human or veterinary use. Statements have not been evaluated by the FDA.